LENZ vs. ALGS, ENTX, TSBX, CDTX, GNTA, IKNA, AVRO, ELUT, DTIL, and TIL
Should you be buying LENZ Therapeutics stock or one of its competitors? The main competitors of LENZ Therapeutics include Aligos Therapeutics (ALGS), Entera Bio (ENTX), Turnstone Biologics (TSBX), Cidara Therapeutics (CDTX), Genenta Science (GNTA), Ikena Oncology (IKNA), AVROBIO (AVRO), Elutia (ELUT), Precision BioSciences (DTIL), and Instil Bio (TIL). These companies are all part of the "biological products, except diagnostic" industry.
Aligos Therapeutics (NASDAQ:ALGS) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk.
LENZ Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -607.03%. Aligos Therapeutics' return on equity of -33.12% beat LENZ Therapeutics' return on equity.
Aligos Therapeutics has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aligos Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.
60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 16.5% of Aligos Therapeutics shares are held by company insiders. Comparatively, 38.4% of LENZ Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Aligos Therapeutics received 18 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 62.16% of users gave Aligos Therapeutics an outperform vote.
LENZ Therapeutics has a consensus target price of $31.33, indicating a potential upside of 90.71%. Given Aligos Therapeutics' higher possible upside, analysts plainly believe LENZ Therapeutics is more favorable than Aligos Therapeutics.
In the previous week, Aligos Therapeutics had 1 more articles in the media than LENZ Therapeutics. MarketBeat recorded 5 mentions for Aligos Therapeutics and 4 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.41 beat Aligos Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.
Summary
Aligos Therapeutics beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.
Get LENZ Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LENZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LENZ Therapeutics Competitors List
Related Companies and Tools
